Stocktube video
29/01/2014

Angle plc aims to signs more deals

View full size
Additional Information
Market: AIM
Sector: Support Services
EPIC: AGL
Latest Price: 76.50p  (2.00% Ascending)
52-week High: 103.00p
52-week Low: 56.00p
Market Cap: 34.61M
1 year chart More charts
Deal AGL Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ANGLE plc
www.angleplc.com
Deal ANGLE plc Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

ANGLE is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. ANGLE also owns a successful specialist technology consultancy and a major investment in a business with a unique computer graphics technology platform.

Pdf

ANGLE’s Novocellus starts EmbryoSure clinical trial

April 11 2012, 7:51am Novocellus reckons EmbryoSure has the potential to increase pregnancy rates by a quarter and possibly by as much as 40 per cent.

ANGLE (LON:AGL) said its 92 per cent held Novocellus business has started the clinical trial for the EmbryoSure product used in in-vitro fertilisation (IVF).

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the amended EmbryoSure trial and patient recruitment starts this week.

Novocellus plans to recruit around 400 patients and the trial is scheduled for completion in mid-year 2013.  Product launch in the UK is anticipated in mid-year 2014.

Four leading UK IVF clinics are participating in the trial, namely: IVF Hammersmith Ltd at Hammersmith Hospital; CARE Fertility in Manchester, the UK's largest independent provider of assisted conception cycles; The Leeds Centre for Reproductive Medicine (LCRM) and the Hewitt Centre for Reproductive Medicine at Liverpool Women's NHS Foundation Trust.

Novocellus has a partnership with Danish group ORIGIO, a supplier of specialised IVF products. ORIGIO has the right to license the EmbryoSure intellectual property in exchange for milestone payments and a royalty on future net sales.

The business secured a second patent for EmbryoSure in the US, extending the period during which Novocellus would receive royalties.

If the EmbryoSure trials are successful, the royalty potential for Novocellus if the product is adopted across ORIGIO's entire existing customer base is circa £25 million per annum.

The impact of the second Novocellus patent granting will potentially translate into additional cumulative royalty income of more than £150 million to Novocellus.

The science behind the product was developed by the University of York, and it tests the amino acid profile of the culture medium used to carry the fertilised egg.  

ANGLE believes EmbryoSure will identify with 95 per cent confidence which one of the embryos is likely to be a top quartile embryo. Currently there is no such means of identifying the best eggs.

Novocellus reckons EmbryoSure has the potential to increase pregnancy rates by a quarter and possibly by as much as 40 per cent.

ANGLE operates as a specialist medical technology company with products in cancer diagnostics and fetal health, and it also owns a specialist technology consultancy.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.